R. Malaviya et al., Targeting Janus kinase 3 in mast cells prevents immediate hypersensitivityreactions and anaphylaxis, J BIOL CHEM, 274(38), 1999, pp. 27028-27038
Janus kinase 3 (JAK3), a member of the Janus family protein-tyrosine kinase
s, is expressed in mast cells, and its enzymatic activity is enhanced by Ig
E receptor/Fc epsilon RI cross-linking Selective inhibition of JAK3 in mast
cells with 4-(4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline) (WHI-P131
) blocked the phospholipase C activation, calcium mobilization, and activat
ion of microtubule-associated protein kinase after IgE receptor/Fc epsilon
RI cross-linking. Treatment of IgE-sensitized rodent as well as human mast
cells with WHI-P131 effectively inhibited the activation-associated morphol
ogical changes, degranulation, and proinflammatory mediator release after s
pecific antigen challenge without affecting the functional integrity of the
distal secretory machinery. In vivo administration of the JAK3 inhibitor W
HI-P131 prevented mast cell degranulation and development of cutaneous as w
ell as systemic fatal anaphylaxis in mice at nontoxic dose levels. Thus, JA
K3 plays a pivotal role in IgE receptor/Fc epsilon RI-mediated mast cell re
sponses, and targeting JAK3 with a specific inhibitor, such as WHI-P131, ma
y provide the basis for new and effective treatment as well as prevention p
rograms for mast cell-mediated allergic reactions.